Daily Stock List
Socket Mobile, Inc. (SCKT)
Stock Oodles, StreetInsider, and PennyStocks24 reported previously on Socket Mobile, Inc. (SCKT), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Established in 1992, Socket Mobile, Inc. is a pioneering provider of mobile productivity solutions. It is a leading innovator of data capture solutions for enhanced productivity in retail point of sale (POS), field service, healthcare, and other mobile markets. The Company’s revenue is chiefly driven by third party developer deployment of barcode enabled mobile applications. Socket Mobile is based in Newark, California.
The Company has key partners in healthcare, hospitality, and other important markets. It offers durable and customizable mobile devices, award-winning software utilities, and all of the essential barcode, RFID, mPOS and data communication peripherals. Its portfolio includes cordless handheld barcode scanners for tablets and smartphones.
Socket Mobile has a strong network of over 1400 registered developers utilizing its software developer’s kit to tightly integrate and enable sophisticated barcode scanning into their applications. The Company’s products include Series 7: Colorful Bluetooth Barcode Scanner, and Durable Bluetooth Barcode Scanner; and Series 8: Attachable Bluetooth Barcode Scanner. In addition, its products include Series 9: Wearable Hands-free Bluetooth Barcode Scanner; and SoMo®: Windows Embedded Mobile Device.
In September 2015, Socket Mobile announced that it released the latest version of its industry leading Cordless Hand Scanner Software Developer Kit (SDK), SocketScan version 10.2. This latest version is compatible with Apple's iOS 9 operating system, Google's Android M (Marshmallow) and Microsoft® Windows® 10. Additionally, it includes numerous new features, benefits and improvements, such as quicker Bluetooth reconnect times.
At the National Retail Federation (NRF) annual Expo this past January, Socket Mobile presented and demonstrated new product offerings. It presented DuraScan, which is an updated durable line of barcode scanners and DuraCase for its Series 8 Scanners featuring RAM® IntelliSkin™ and GDS Technology™. The Company additionally previewed the new Socket Mobile TouchPoint™ platform to demonstrate how NFC (Near Field Communication), barcode scanning, and Bluetooth® Low Energy enrich the shopping experience through interacting with the customer's SmartPhone.
In February, Socket Mobile reported record profits for Q4 and full year ended December 31, 2015. Revenue for the 2015 full year totaled $18.4 million. This represents an increase of 8 percent versus revenue of $17.0 million for 2014. Net income for 2015 was $1.8 million, or $0.33 per share, versus net income of $0.4 million, or $0.09 per share, in 2014. Annual gross margins on revenue increased to 48.6 percent in 2015 from 43.6 percent in 2014. Annual operating expenses for 2015 were $6.8 million. This represents an increase of 5 percent versus annual operating expenses for 2014 of $6.5 million.
Socket Mobile, Inc. (SCKT), closed Wednesday's trading session at $3.00, up 4.90%, on 24,687 volume with 46 trades. The average volume for the last 60 days is 8,469 and the stock's 52-week low/high is $1.82/$3.25.
Genius Brands International, Inc. (GNUS)
TopPennyStockMovers and RedChip reported earlier on Genius Brands International, Inc. (GNUS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Beverly Hills, California- based Genius Brands International, Inc. is a worldwide brand management enterprise. The Company creates and licenses multimedia content for toddlers to tweens. Genius Brands creates "content with a purpose". This means content that is as entertaining as it is enriching. A Squared Entertainment is a wholly-owned subsidiary of Genius Brands International. Genius Brands’ A Squared Entertainment is a brand management and licensing company.
Genius Brands’ growing library of content includes the award-winning Baby Genius, Warren Buffett's Secret Millionaires Club, Thomas Edison's Secret Lab, and Llama Llama, from the New York Times bestselling children's book franchise, and Stan Lee's Mighty 7, the first project from Stan Lee Comics, a joint venture with Stan Lee's POW! Entertainment.
Genius Brands’ A Squared Entertainment represents third-party properties across a wide array of categories in territories globally. At present, A Squared Entertainment represents Psycho Bunny, a luxury apparel line; From Frank, a humor greeting card and product line; as well as Celessence Technologies, the world's foremost microencapsulation company.
An academic team headed by Professor Emeritus, Don Roberts, and a team of Emmy Award winning writers developed Thomas Edison's Secret Lab. This ensures it’s E/I (Educational/Informational) compliant per FCC standards. Thomas Edison's Secret Lab is a fully immersive multimedia property. It encourages children to engage themselves in the fun and exploration of science.
Last month, Genius Brands International announced that it and Sony Pictures Home Entertainment (SPHE) finalized a multi-year agreement. SPHE will provide marketing and distribution of Genius Brands’ Kid Genius and Baby Genius labels, throughout North America. Moreover, the deal allows SPHE and Genius Brands to co-develop, distribute, and internationally merchandise future animated or live action properties derived from their respective programming libraries.
This week, Genius Brands International named former Kabillion executive and respected distribution, production, licensing and merchandising expert Debra Pierson as general manager of its Kid Genius entertainment channel on Xfinity On Demand, delivering "Smart TV for Kids." As VP Sales and Marketing for Kabillion (February 2007-December 2012), she helped launch the Kabillion Kids VOD channel -- now available in more than 60 million homes through all major cable providers -- on Comcast, Time Warner and Charter.
Genius Brands International, Inc. (GNUS), closed Wednesday's trading session at $0.984, up 2.49%, on 59,037 volume with 13 trades. The average volume for the last 60 days is 32,425 and the stock's 52-week low/high is $0.625/$3.35.
AntriaBio, Inc. (ANTB)
Ceocast News and PennyStocks24 reported previously on AntriaBio, Inc. (ANTB), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
AntriaBio, Inc. is a biopharmaceutical company concentrating on developing novel extended release therapies. The Company develops novel extended release therapies through combining proprietary formulation and manufacturing capabilities with well-known molecules to considerably improve standards of care. It develops innovative approaches to fulfill unmet clinical needs through applying its formulation capabilities to improve existing therapies.
AntriaBio’s lead product candidate is AB101. This is an injectable once-weekly basal insulin for type 1 and type 2 diabetes. AB101 addresses a $10 billion market where the present standard of care is a once-daily basal insulin injection. AB101 is formulated from human recombinant insulin. This is different from existing basal insulin replacement therapies that use synthetic insulin analogues.
AB101 is now in preclinical development. It is to be administered by subcutaneous injection. AB101 is intended for use in patients with Type 1 and Type 2 diabetes who require basal insulin for the control of hyperglycemia. The design of the formulation is to release human insulin slowly and uniformly over a period of roughly one week without an adverse initial burst of insulin.
AntriaBio successfully completed a series of in vitro and multi-species animal pharmacology studies for AB101. The studies assessed the receptor pharmacology, pharmacokinetics, and pharmacodynamics of AB101 and support potential proof-of-concept for a once-weekly basal insulin in patients.
In September 2015, AntriaBio announced the addition of a new product candidate to the Company’s product development pipeline – AB301. As a potential treatment for patients with type 2 diabetes, AB301 is a weekly injectable combination of a pegylated human glucagon-like peptide-1 (GLP-1) agonist and AB101, AntriaBio's basal insulin lead product candidate. In vitro and in vivo studies completed to date (as of the September 16, 2015 press release) indicated that AB301 has the potential to be a well-tolerated, effective therapy for type 2 diabetes.
This past November, AntriaBio announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/324,734 titled, "Solvent Extraction From Biodegradable Microparticles." This application covers the methods around solvent extraction and rinse in the manufacturing process for product candidates AB101 and AB301, and also other internal and external potential pipeline therapies that use the Company’s proprietary microsphere drug delivery platform.
AntriaBio, Inc. (ANTB), closed Wednesday's trading session at $1.05, up 5.00%, on 3,970 volume with 10 trades. The average volume for the last 60 days is 10,183 and the stock's 52-week low/high is $0.8001/$2.25.
CytoDyn, Inc. (CYDY)
StockOodles, PennyStockRumors.net, and AllPennyStocks reported on CytoDyn, Inc. (CYDY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
CytoDyn, Inc. is a biotechnology company headquartered in Vancouver, Washington. It is centering on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection - PRO 140. PRO 140 has finished Phase 2 clinical trials with demonstrated antiviral activity in man. It is presently in Phase 3.
PRO 140 is CytoDyn’s novel self-injectable antibody for the treatment of HIV. PRO 140 is a humanized monoclonal antibody directed against CCR5, a molecular portal that HIV utilizes to enter cells. PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors. The intention of these are to protect healthy cells from viral infection. PRO 140 blocks the HIV co-receptor CCR5. Clinical trial results to date indicate that it does not affect the normal function of the cell.
PRO 140 has been the subject of Phase 1/1b and Phase 2a clinical trials. Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can considerably decrease viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. CytoDyn’s goal is to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.
Furthermore, PRO 140 has been designated a "fast track" product candidate by the Food and Drug Administration (FDA). The PRO 140 antibody appears to be a strong antiviral agent leading to potentially less side effects and less frequent dosing requirements in comparison to daily drug therapies now utilized.
CytoDyn has reached an agreement with the FDA on the Company's previously submitted Phase 3 protocol synopsis for PRO 140. Its Phase 3 protocol provides for a 25-week study with 300 HIV patients. CytoDyn’s completed Phase 2b treatment substitution trial demonstrated that 98 percent of all patients treated with PRO 140 successfully passed four weeks of monotherapy without virologic failure. CytoDyn said that Company research data has expanded the potential clinical indications for PRO 140 to include certain inflammatory diseases, autoimmunity, transplantation, and cancer.
This week, CytoDyn announced that clinical findings from its PRO 140 monotherapy phase 2b study will be presented in an oral slide session at the ASM Microbe 2016 Conference from June 16-20 in Boston, Massachusetts. ASM Microbe 2016 is the merger of the American Society for Microbiology’s two first-rate events, the ASM General Meeting and ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy).
CytoDyn, Inc. (CYDY), closed Wednesday's trading session at $1.00, up 6.38%, on 1,065,141 volume with 671 trades. The average volume for the last 60 days is 196,976 and the stock's 52-week low/high is $0.63/$1.40.
1pm Industries, Inc. (OPMZ)
SMS Penny Picks and StockHideout reported this month on 1pm Industries, Inc. (OPMZ), SmallCapVoice and Cannabis Financial Network News did earlier, and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
1pm Industries, Inc.’s business centers on the sale and distribution of medical marijuana under the award-winning brand, Von Baron Farms. It launched www.vonbaronlabs.com, which sells the Company's complete CBD line. Products can be purchased by anyone and shipped anywhere in the U.S. 1pm Industries’ shares trade on the OTC Markets Group’s OTCQB. 1pm Industries has its corporate headquarters in Beverly Hills, California.
Von Baron Labs’ products are extracted from industrial hemp plants. They contain no THC, which is the psychoactive constituent in marijuana. The CBD hemp oil extracts in any form are legal in every State in the U.S.
1pm Industries’ Nano-CBD are ion-sized nutrients of CBD encased with water molecules. Because of their extremely small size, nano-particles ingested in food and water are basically different. Additionally, they can move throughout the body in advanced ways by way of cells' membranes. Usually, only 7-10 percent of CBD ingested is absorbed and used by the body. Yet, nanotechnology enables the body to absorb up to 95 percent of the CBD.
1pm Industries’ CBD product line includes 50 mg and 100mg CBD versions of its multiple award winning Cookie Spread; CBD Shots; BuzzKill, which contains 50Mg of CBD; Shake and Pour Pancake and Waffle Mix, as well as CBD Gummie.
Today, 1pm Industries announced that it has launched its CBD Shot and E-Commerce Site for its Nano-Cannabidiol (Nano-CBD) product line. 1pm Industries’ CBD shot is a 1.9 ounce CBD shot with the equivalent of 100mg of CBD. The Company stated that its CBD Shot has some anti-pain, anti-inflammatory, and anti-anxiety benefits. However, this is without any type of high.
The CBD Shot doesn't put a person to sleep. It calms a person down and it permits one to deal with things. 1pm Industries shipped samples to dispensaries. The Company will commence taking orders next week.
1pm Industries, Inc. (OPMZ), closed Wednesday's trading session at $0.335, up 34.27%, on 310,988 volume with 148 trades. The average volume for the last 60 days is 12,594 and the stock's 52-week low/high is $0.0338/$2.20.
Lingo Media Corp. (LMDCF)
The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.6504, up 11.18%, on 9,500 volume with 4 trades. The stock’s average daily volume over the past 60 days is 4,322, and its 52-week low/high is $0.0862/$0.6745.
Lingo Media Corp. is pleased to announce the hiring of Luis Ortiz. Mr. Ortiz comes to the Company with more than 20 years of experience in sales and sales management in Latin America where he has been instrumental in delivering significant sales growth for his previous employers, Wi-LAN Inc. and SMART Technologies. Mr. Ortiz joins the Company's ELL Technologies division as Director of Sales, Latin America. He brings industry insight and sales expertise that will help deliver the company's cutting-edge suite of English language training solutions to channel partners, distributors, and direct sales clients throughout the region.
Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.
The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.
Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.
Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer
Lingo Media Corp. Company Blog
Lingo Media Corp. News:
Lingo Media to Expand Latin America Sales Channel With Strategic Hire
Lingo Media's ELL Technologies to Launch "ELL Studio" App
Lingo Media Selected to the 2016 TSX Venture 50 & Ranked #1 In the Diversified Industries Sector
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.768, up 20.00%, on 256,472 volume with 90 trades. The stock’s average daily volume over the past 60 days is 29,279, and its 52-week low/high is $0.20/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) is an integrated energy storage solutions company focused on the design, development and manufacture of high-quality cells, batteries and power systems. The company's innovative 'Made in the U.S.A.' product line includes multiple lithium-ion technologies and form factors that are optimized to address three high-demand target markets – including stationary and grid storage; motive applications, such as electric and hybrid electric fleet vehicles; and specialty applications, such as military, aerospace, marine, medical and telecom backup.
Through a recent restructuring of its operations, Oakridge strategically positioned itself to expand its market reach moving forward. The company currently owns and operates two manufacturing facilities in Melbourne, Florida, which play an instrumental role in its efforts to meet the growing demand for its cutting-edge large format Pro Series golf car batteries and its small format Patriot Series RC batteries. These operations also allow Oakridge to bring stable employment opportunities back to the U.S., effectively highlighting its tireless commitment to the revitalization of the country's manufacturing industry.
The company also maintains a presence on the international stage through its recently formed subsidiary, Oakridge Global Energy Solutions Limited, Hong Kong. This subsidiary, which is expected to serve as the foundation for Oakridge's sales efforts throughout the Asia-Pacific region, was created primarily to address the tremendous international demand for its revolutionary stored energy solutions. The company also maintains a substantial interest in Leclanche S.A., a Swiss developer and manufacturer of large-sized lithium-ion batteries that was originally founded in 1909.
Oakridge has indicated plans to expand its presence in a collection of markets throughout Europe and Asia as it continues to build upon its established product development and manufacturing infrastructure. The company will lean on the expertise of its proven management team – which includes well over a century of combined industry experience – as it looks to increase its share of the $12 billion domestic battery manufacturing industry. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Energy Announces Start of Operations at New Manufacturing Facility
Revenue Guidance Q1 FY2016 First Commercial Revenues in the Company’s History
Oakridge Global Energy Solutions Investor Conference Call - Tuesday March 22
Immune Therapeutics, Inc. (IMUN)
The QualityStocks Daily Newsletter would like to spotlight Immune Therapeutics, Inc. (IMUN). Today, Immune Therapeutics, Inc. closed trading at $0.162, up 15.71%, on 333,490 volume with 54 trades. The stock’s average daily volume over the past 60 days is 202,421, and its 52-week low/high is $0.045/$0.36.
Immune Therapeutics, Inc. (IMUN) is a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect persons around the world. Building on the power of the body's natural immune system, the company's pipeline of products and immunotherapy technologies are designed to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.
Immune Therapeutics' most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its low dose naltrexone product (LDN), internationally known as Lodonal™, both of which have been shown to stimulate immune systems even in patients with advanced cancer.
Additionally, Immune Therapeutics is pursuing additional investigations for MENK and LDN as viable treatments for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
Immune Therapeutics and partners AHAR Pharma and GB Pharma Holdings recently completed a bridging trial to determine the safety and efficacy of LDN in patients with HIV, and have submitted data in connection with the filing of its New Drug Application for LDN with The National Agency for Food and Drug Administration and Control, (NAFDAC) of Nigeria. Disclaimer
Immune Therapeutics, Inc. Company Blog
Immune Therapeutics, Inc. News:
Immune Therapeutics, Inc. (IMUN) Using the Power of the Body to Fight Cancer and AIDS
Immune Therapeutics, Inc., Appoints Two New Board Members
Immune Therapeutics, Inc to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016
GTX Corp. (GTXO)
The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.0138, up 10.40%, on 91,039 volume with 6 trades. The stock’s average daily volume over the past 60 days is 287,216, and its 52-week low/high is $0.005/$0.02.
GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.
GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.
The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.
As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.
"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer
GTX Corp. Company Blog
GTX Corp. News:
Security Experts Discuss Threats and Solutions on SecuritySolutionsWatch.com
GPS SmartSole Showcased With Telefónica at CeBIT 2016
GTX Corp Granted New Communication Protocol Patent Under Family Tree Patent 286
Cherubim Interests, Inc. (CHIT)
The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0001, even for the day. The stock’s average daily volume over the past 60 days is 20,779,176, and its 52-week low/high is $0.0001/$0.33.
Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.
The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.
Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.
Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer
Cherubim Interests, Inc. Company Blog
Cherubim Interests, Inc. News:
Moving Ahead of Averages, Technical Review -- Research on Saleen Automotive, Cherubim Interests, Fission Uranium, and Pure Biosciences
Cherubim Interests, Inc. Signs MOU to Acquire Revenue-Producing Company
Cherubim Interests Inc. Announces FINRA Approval of Convertible Preferred Stock Dividend
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Agora Holdings, Inc. (AGHI) to Introduce Details of New Platform Next Week
- Alternet Systems (ALYI) Data Analytics Solution Gains Momentum with New Clients and Partners
- Cherubim Interests, Inc. (CHIT) Signs MOU to Acquire Revenue-Producing Company
- Dominovas Energy Corp. (DNRG) Recognized as Leader in Expanding Fuel Cell Applications in U.S. Department of Energy (DOE) Report
- FlexWeek, Inc. (FXWK) Announces Engagement of QualityStocks Corporate Communications Suite
- Giggles N' Hugs, Inc. (GIGL) CEO Discusses 2016 Growth Strategies in Second QualityStocks Interview
- GTX Corp. (GTXO) GPS SmartSole Showcased With Telefónica at CeBIT 2016
- Halitron, Inc. (HAON) Finalizes Third Acquisition in 2016
- Immune Therapeutics, Inc. (IMUN) Appoints Two New Board Members
- International Stem Cell Corp. (ISCO) to Raise $6.3 Million Through a Private Placement to Fund Phase I Clinical Trial
- Lingo Media Corp. (LMDCF) ELL Technologies to Launch "ELL Studio" App
- Moxian, Inc. (MOXC) Enters Into Exclusive Agreement and Development Partnership With Xinhua Media Affiliate
- Oakridge Global Energy Solutions, Inc. (OGES) Investor Conference Call - Tuesday March 22
- OurPet's Company (OPCO) Reaches a Settlement With Competitor Over Durapet(R) Patents
- Star Mountain Resources Inc. (SMRS) Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine
- View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.